



**BILFINGER**

**Bilfinger SE**

# Quarterly Statement Q4 and Preliminary Figures FY 2018

February 14, 2019

## FY 2018: Earnings expectations met, cash and growth targets exceeded

	Outlook FY 2018	Actual FY 2018	
<b>Orders received</b>	Organic growth in the mid single-digit percentage range	+12%	✓ ✓
<b>Revenue</b>	Organically stable to slightly growing	+6%	✓
<b>EBITA adj.</b>	Significant increase to mid-to-higher double-digit-million € amount, i.e. range of €50 to €75 million	€65 million	✓
<b>Free cash flow adj.</b>	Break-even	€56 million	✓ ✓

# FY 2018: Strong order book drives future revenue growth



## Orders received

FY 2018: organic growth of 12%, book-to-bill ratio of 1.07  
Q4: organic increase of 3%



## Revenue

FY 2018: organic growth of 6% exceeded expectations  
Q4: organic increase of 4%



## EBITA adjusted

FY 2018: significant increase to €65m, margin at 1.6%  
Q4: once again strongest quarter



## Net profit

FY 2018: still negative, but significantly improved





# FY 2018: Strong cash development in fourth quarter

## Liquidity



Adjusted free cash flow significantly improved to €56m, DSO improvement by 14 days in Q4  
Reported free cash flow close to break-even

## Balance sheet / dividend



Solid balance sheet, maintain baseline dividend proposal<sup>1)</sup> of €1.00 per share;  
share buyback plan completed October 31, 2018

## Outlook 2019



Continued organic growth of orders received and revenue  
Further significant increase in adjusted EBITA to more than €100m

<sup>1)</sup> Intended dividend proposal of Executive Board, subject to a corresponding resolution from the Supervisory Board



# Overall positive market outlook

## Update on market developments (1/2)

### Continental Europe

#### Oil & Gas

- Maintenance & field life extension investments continue.
- Upgrades along the “European gas network”



#### Chemicals & Petrochem

- Stable maintenance business
- Demand for general contractor solutions within maintenance projects
- Turn-around pipeline filling fast
- Willingness for further contracting-out of maintenance depends on country/region



#### Energy & Utilities

- CHP / district heating
- Perceived increase of contracting-out rate in maintenance
- Distributed power generation
- Focus on renewable energy and digitalization



#### Pharma & Biopharma

- Few investments but large projects
- Good activity around ‘modules’
- Market remains positive but slowing dynamic
- Price-driven maintenance for pharma



### North-west Europe

- Record profits & cash for many O&G customers
- Maintenance backlog being addressed
- O&G majors continuing to offload later life assets but and investing in new fields



- Chemical / downstream investments and expansions continue
- IMO 2020 beginning to impact refinery upgrades
- Chemical companies becoming more interested in plastic to X technologies



- Majors maintaining focus on renewables market
- Wylfa nuclear project suspended
- Hinkley Point continues on track



\*International Maritime Organization:  
date for ships to comply with low sulphur fuel oil requirement

\*\*Electrical & Instrumentation


Significant markets for Bilfinger (based on current revenue)

# Oil & Gas and Chemicals & Petrochemicals show positive outlook in our growth regions


## Update on market developments (2/2)

### North America


#### Oil & Gas

- Number of active drilling rigs ramp-up and stable 
- Mid-stream gas investments continue
- Gulf of Mexico picking up
- LNG new builds announced


#### Chemicals & Petrochem

- American Chemical Council confirms growth with slowing pace in general, however 
- Gas monetization expansion on the US Gulf Coast continues


#### Energy & Utilities


- Energy storage market is expected to double 
- Trend towards renewable energy continues and becomes competitive due to decreasing CAPEX


#### Pharma & Biopharma


- US is largest market in the world 
- Single use batch processing is rising
- Rising investment in Biopharmaceutical R&D (personalized medicines)

### Middle East

- Oil & Gas upwards trend fueled by NOC investments 
- Major opportunities in the pipeline in gas and upstream oil
- Environmental tech in focus
- The OPEX market remains solid and steady

- Petrochemical market steady on Opex and upbeat on Capex 
- Shifting Capex to integrate the value chain to consumer spots leading to multiple ME funded American and Asian projects
- Refining under margin pressure; focus on Opex optimization creates opportunity

- Energy utility (conventional) under pressure due to arrival of renewable revolution to Middle East as well as excess thermal capacity 
- Energy efficiency back on the agenda
- Electrical Energy demand plateauing


- Expected market growth in the next few years due to pressure on localization 

 Significant markets for Bilfinger (based on current revenue)


## **Financials Q4 and Preliminary Figures FY 2018**

# Strong order book

## Development of orders received




- **Orders received:**  
FY: +10% above prior year (org.: +12.5%), with especially strong order momentum in E&T
- Q4: y-o-y increase in E&T and MMO, decrease in OOP
- **Book-to-bill:** FY 1.07
- **Order backlog:**  
+11% above prior year (org.: +12%)





# Revenue growth continues, Q4 remains strongest quarter

## Development of revenue and profitability



**EBITA adj. (€ million)**




**EBITA (€ million)**



- **Revenue:**  
FY: Increase of +3% (org. +6%), strong book and bill
- **EBITA adj.:**  
FY: Increase as expected, margin up to 1.6%, Q4 strongest quarter with 3.3%
- **Special items:**  
FY: Decrease in special items: €72 million compared to €121 million in prior year, thereof €17 million from non-cash disposal losses;  
Compliance, IT, Restructuring in total €55 million

# Gross profit with 20bps quarter-on-quarter improvement


Adjusted gross profit (€ million)



- Full year with y-o-y improvement; prior year was burdened by project risk provisions
- Future improvement by
  - portfolio optimization
  - growth in higher-margin business (marine / nuclear / biopharma)
  - continued execution improvements
- FY 2018:
  - Amortization €5m
  - Depreciation €65m

# Stable y-o-y SG&A supporting growth with increased start-up costs of ~20m EUR for business development and digitalization

## Adjusted selling and administrative expenses (€ million)



- Adjusted SG&A ratio in FY18 improved to 8.7% despite increased expenses for business development and digitalization
- Q4 2017 was impacted by positive reclassification effects, run-rate has been and still is at approx. € 90m per quarter
- Target 2020 confirmed: 7.5% of revenue
- Positive effects in administration costs from efficiency and process optimization programs  
Further reduction in number of legal entities and strengthening system support

# Initiatives for higher efficiency and lower costs

## IT PROJECTS

### Status of process and system harmonization (ERP-System):

- ✓ Template solution set up
- ✓ Degree of completion: 40%
- ✓ Targeting ~70% by end of 2019

## PROCUREMENT INITIATIVE

- ✓ Increasing number of e-auctions to improve the competitive advantage
- ✓ Reduced prices for direct material by further bundling across entities
- ✓ Focus on best price structures for products like scrubbers


## MERGER OF OPERATING UNITS

### Example Austria: realizing cost synergies by full merger

- ✓ Reduction from 5 to 1 legal entities by merger, roll-in of ERP System
- ✓ Joint go-to-market
- ✓ Full life cycle, i.e. engineering, procurement, construction, maintenance
- ✓ Ability to serve all focus industries


## REDUCTION IN THE NUMBER OF LEGAL ENTITIES

*Complexity reduction within the organization through significant simplification of legal structure*




# E&T: visible improvements, but still mixed performance within segment

## Development of revenue and profitability



### Book-to-bill ratio



### EBITA adj. (€ million)




- Orders received:**  
FY: Strong increase: +32% (org. +34%) compared to low prior-year figure, book-to-bill 1.2  
Q4: +28% (org. +26%); strong performance in Biopharma and North America
- Order backlog:**  
€1,002 million / +34% (org. +33%)
- Revenue:**  
FY: Growth of +7% (org. +8%)  
Q4: Increased by +17% (org. +17%), significant contribution from North America
- EBITA adjusted:**  
Still mixed performance within segment; margin at 2.2%



# MMO: Progressive EBITA adj. margin improvement

## Development of revenue and profitability



### Book-to-bill ratio



### EBITA adj. (€ million)



- Orders received:**

FY: Increase of +7% (org. 9%), book-to-bill at 1.05

Q4: Increase of +7% (org. 7%), book-to-bill at Q4 1.03; especially good growth in Oil & Gas and Petrochem

- Order backlog:**

€1,717 million, i.e. increase of +6% (org. +6%)

- Revenue:**


FY: Increase of +5% (org. +6%), stable development quarter-on-quarter

- EBITA adjusted margin:**

FY: 4.0%, i.e. at prior-year level

Q4: increase to 5.8%, esp. strong in Northwest Europe

# OOP<sup>1)</sup>: Two of four “accretive” entities will be sold by end of Q1 2019



- M&A progress on track:**

**Dilutive:** all 13 entities disposed or terminated in 2018

**Accretive:** out of four entities, one signed, one closed

Consequently a book loss of €9 million in Q4 2018 and a book gain of €5 million in Q1 2019

Related ~€30 million cash-inflow expected in Q1 2019

- Business development:**


**Revenue** Q4 declining by -17% due to sale of “dilutive” entities, organic +4%

**EBITA adj.** Q4 year-on-year decrease from €4 million to €3 million, mainly due to maintenance postponements in South Africa

1) Part of Reconciliation Group


# Cash turnaround with exceptionally strong Q4

## Adjusted operating cash flow<sup>1</sup> (€ million)




<sup>1</sup> Adjustments correspond to EBITA adjustments, partial time offset in cash flow


## Net profit (€ million)



## Adjusted net profit (€ million)




## Net Trade Assets (€ million)



DSO: Trade receivables + WIP - advance payments received, DPO: Trade payables

## Net cash (€ million)




## Outlook 2019: next step on our way to reach targets

<i>in € million</i>	Actual FY 2018	Expected FY 2019
<b>Revenue</b>	4,153	Mid single-digit organic growth
<b>EBITA adjusted</b>	65	Significant increase to more than €100 million
<b>Free Cash Flow reported</b>	-4	Positive <sup>1)</sup>

1) Including positive effect from first-time application of IFRS16, like-for-like: break-even

# Bilfinger 2020

## Further progress in build-up phase





# **Quarterly Statement Q4 2018 and Preliminary Figures FY 2018**

## **Financial backup**

# Segment overview FY 2018

	E&T			MMO			Reconciliation Group						Group		
							HQ / Consolidation / other			OOP					
€ million	FY 2018	FY 2017	Δ in %	FY 2018	FY 2017	Δ in %	FY 2018	FY 2017	Δ in %	FY 2018	FY 2017	Δ in %	FY 2018	FY 2017	Δ in %
Orders received	1,479	1,119	32%	2,854	2,664	7%	-45	-15	-202%	171	286	-40%	4,459	4,055	10%
Order backlog	1,002	747	34%	1,717	1,623	6%	-20	-10	-92%	118	172	-31%	2,818	2,531	11%
Revenue	1,235	1,157	7%	2,758	2,628	5%	-35	-34	-2%	195	293	-33%	4,153	4,044	3%
Investments in P, P&E	10	8	25%	41	48	-15%	4	3	33%	11	11	0%	66	71	-6%
Depreciation P, P&E	-10	-10	0%	-39	-41	5%	-5	-5	0%	-11	-16	31%	-65	-72	9%
Amortization	-4	-6	33%	-1	-1	0%	0	0	0%	0	-1	100%	-5	-8	38%
EBITDA adjusted	37	-14	n/a	149	144	3%	-64	-67	4%	8	12	-33%	130	75	73%
EBITA	9	-43	n/a	106	88	21%	-142	-194	27%	-1	-12	92%	-7	-118	94%
EBITA adjusted	27	-24	n/a	110	103	7%	-69	-72	4%	-3	-4	25%	65	3	1,927%
EBITA adjusted margin	2.2%	-2.1%		4.0%	3.9%					-1.4%	-1.2%		1.6%	0.1%	

# Segment overview Q4 2018

	E&T			MMO			Reconciliation Group						Group		
							HQ / Consolidation / other			OOP					
€ million	Q4 2018	Q4 2017	Δ in %	Q4 2018	Q4 2017	Δ in %	Q4 2018	Q4 2017	Δ in %	Q4 2018	Q4 2017	Δ in %	Q4 2018	Q4 2017	Δ in %
Orders received	351	273	28%	749	701	7%	-12	-5	-147%	26	116	-78%	1,114	1,085	3%
Order backlog	1,002	747	34%	1,717	1,623	6%	-20	-10	-92%	118	172	-31%	2,818	2,531	11%
Revenue	362	308	18%	713	716	-0%	-14	-7	-100%	54	65	-17%	1,115	1,082	3%
Investments in P, P&E	3	2	50%	11	11	0%	1	1	0%	4	5	-20%	19	19	0%
Depreciation P, P&E	-2	-2	0%	-10	-11	10%	-1	0	n/a	-3	-5	40%	-16	-18	11%
Amortization	-1	-2	50%	0	0	n/a	0	0	0%	0	0	0%	-1	-2	50%
EBITDA adjusted	17	17	0%	51	49	4%	-21	-18	-17%	6	10	-40%	53	58	-9%
EBITA	6	13	-54%	37	27	37%	-54	-38	-42%	5	0	n/a	-6	2	n/a
EBITA adjusted	15	15	0%	41	38	8%	-22	-18	-22%	3	5	-40%	37	40	-8%
EBITA adjusted margin	4.1%	5.0%		5.8%	5.2%					6.3%	6.9%		3.3%	3.7%	

## P&L (1/2)

€ million	Q4/18	Q4/17	Δ in %	FY/18	FY/17	Δ in %	
Revenue	1,115	1,082	3%	4,153	4,044	3%	+3%, organically +6%
Gross profit	118	112	5%	391	336	16%	
Selling and administrative expense	-110	-86	-28%	-403	-395	-2%	
Impairment losses and reversal of impairment losses according to IFRS 9	2	0	n/a	0	0	n/a	Significant effects: restructuring expenses -18 (prior year -40), portfolio adjustments -14 (prior year -42),
Other operating income and expense	-24	-30	20%	-14	-81	83%	
Income from investments accounted for using the equity method	7	4	75%	14	14	0%	
<b>EBIT</b>	<b>-7</b>	<b>0</b>	<b>n/a</b>	<b>-12</b>	<b>-126</b>	<b>91%</b>	Following depreciation of property, plant and equipment and amortization of intangible assets of 65 (prior year -72)
<i>Amortization (IFRS3)</i>	<i>1</i>	<i>2</i>	<i>50%</i>	<i>5</i>	<i>8</i>	<i>38%</i>	
<b>EBITA (for information only)</b>	<b>-6</b>	<b>2</b>	<b>n/a</b>	<b>-7</b>	<b>-118</b>	<b>94%</b>	
<i>Special items in EBITA</i>	<i>43</i>	<i>38</i>	<i>13%</i>	<i>72</i>	<i>121</i>	<i>-41%</i>	
<b>EBITA adjusted (for information only)</b>	<b>37</b>	<b>40</b>	<b>-8%</b>	<b>65</b>	<b>3</b>	<b>1,927%</b>	Currency effects €1 million

## P&L (2/2)

€ million	Q4/18	Q4/17	Δ in %	FY/18	FY/17	Δ in %
<b>EBIT</b>	<b>-7</b>	<b>0</b>	<b>n/a</b>	<b>-12</b>	<b>-126</b>	<b>91%</b>
Financial result	1	-4	n/a	15	-12	n/a
<b>EBT</b>	<b>-6</b>	<b>-4</b>	<b>-50%</b>	<b>3</b>	<b>-138</b>	<b>n/a</b>
Income taxes	-5	-3	-67%	-23	-3	-667%
<b>Earnings after taxes from continuing operations</b>	<b>-11</b>	<b>-7</b>	<b>-57%</b>	<b>-20</b>	<b>-141</b>	<b>86%</b>
<b>Earnings after taxes from discontinued operations</b>	<b>1</b>	<b>4</b>	<b>-75%</b>	<b>-3</b>	<b>55</b>	<b>n/a</b>
Minority interest	0	-3	100%	-1	-3	67%
<b>Net profit</b>	<b>-10</b>	<b>-6</b>	<b>-67%</b>	<b>-24</b>	<b>-89</b>	<b>73%</b>
<b>Adjusted net profit<sup>1</sup></b>	<b>23</b>	<b>23</b>	<b>0%</b>	<b>36</b>	<b>-9</b>	<b>n/a</b>
Average number of shares (in thousands)	40,271	43,368	-7%	41,458	43,975	-6%
Earnings per share (in €)	-0.26	-0.14	-86%	-0.59	-2.01	71%
thereof from continuing operations	-0.28	-0.23	-22%	-0.51	-3.25	84%
thereof from discontinued operations	0.02	0.09	-78%	-0.08	1.24	n/a

No capitalization of losses in the domestic tax group of Bilfinger SE

In addition to the special items in EBITA, taxes are also adjusted (normalized tax rate of currently 31%)


<sup>1</sup> from continuing operations



## Special items of ~€30 million (w/o disposal gains/losses) in FY 2019 expected


€ million	Q4 2017	FY 2017	Q1 2018	Q2 2018	Q3 2018	Q4 2018	FY 2018
<b>EBITA</b>	2	-118	-11	-1	11	-6	-7
Disposal gains/ losses, write-downs, selling- related expenses	15	40	-2	-2	0	21	17
Compliance	2	12	3	5	-1	2	9
Restructuring, Extraordinary depreciations	15	50	0	4	7	11	22
IT investments	6	19	4	6	5	9	24
<b>Total Adjustments</b>	<b>38</b>	<b>121</b>	<b>5</b>	<b>13</b>	<b>11</b>	<b>43</b>	<b>72</b>
<b>EBITA adjusted</b>	<b>40</b>	<b>3</b>	<b>-6</b>	<b>12</b>	<b>22</b>	<b>37</b>	<b>65</b>

# Balance Sheet – Overview Assets and Liabilities



Intangible assets	0%
Other non-current assets	-4%
Current assets	3%
Marketable Securities	-20%
Cash and equivalents	-26%
Assets classified as held for sale	317%

compared to  
Dec 31, 2017



Equity	-13%
Pension provisions	-2%
Financial debt	0%
Other non-current liabilities	-11%
Current liabilities	4%
Liabilities classified as held for sale	0%

compared to  
Dec 31, 2017

**Non-current assets** include non-cash purchase price components Apleona (Vendor Claim 117, Preferred Participation Note 237)

**Marketable securities:** 120 in call and time deposits

Decline in **equity** due to share buyback (-112) and dividend payment (-42), adjustments on adoption of IFRS 9 (-17)

**Pension provisions** virtually stable due to only slightly increased interest rate of 1.7%

**Financial debt** relates to bond of 500

**Other non-current liabilities** includes deferred tax assets of 39

# Consolidated Balance Sheet: Assets

€ million	Dec 31, 2018	Sep 30, 2018	Dec 31, 2017
<b>Non-current assets</b>			
Intangible assets	804	807	804
Property, plant and equipment	324	364	367
Investments accounted for using the equity method	35	30	22
Other financial assets	376	373	364
Deferred taxes	75	83	86
	<b>1,614</b>	<b>1,657</b>	<b>1,643</b>
<b>Current assets</b>			
Inventories	62	81	82
Receivables and other financial assets	1,102	1,230	1,031
Current tax assets	23	22	30
Other assets	51	57	55
Marketable securities	120	120	150
Cash and cash equivalents	454	354	617
Assets classified as held for sale	50	0	12
	<b>1,862</b>	<b>1,864</b>	<b>1,977</b>
<b>Total</b>	<b>3,476</b>	<b>3,521</b>	<b>3,620</b>

# Consolidated Balance Sheet: Equity and Liabilities

€ million	Dec 31, 2018	Sep 30, 2018	Dec 31, 2017
<b>Equity</b>			
Equity attributable to shareholders of Bilfinger SE	1,218	1,252	1,408
Attributable to minority interest	-13	-14	-25
	<b>1,205</b>	<b>1,238</b>	<b>1,383</b>
<b>Non-current liabilities</b>			
Provisions for pensions and similar obligations	288	292	293
Other provisions	25	25	27
Financial debt	11	509	509
Other liabilities	0	0	0
Deferred taxes	39	46	45
	<b>363</b>	<b>872</b>	<b>874</b>
<b>Current liabilities</b>			
Current tax liabilities	34	33	34
Other provisions	384	400	442
Financial debt	502	2	2
Trade and other payables	750	765	640
Other liabilities	212	211	219
Liabilities classified as held for sale	26	0	26
	<b>1,908</b>	<b>1,411</b>	<b>1,363</b>
<b>Total</b>	<b>3,476</b>	<b>3,521</b>	<b>3,620</b>

# Group Cash Flow Statement


€ million	FY		Q4	
	2018	2017	2018	2017
<b>Cash flow from operating activities of continuing operations</b>	<b>50</b>	<b>-119</b>	<b>149</b>	<b>48</b>
- <i>Thereof special items</i>	-60	-112	-14	-30
- <i>Adjusted cash flow from operating activities of continuing operations</i>	110	-7	163	78
- <i>Investments in property, plant and equipment and intangible assets</i>	-66	-71	-19	-19
- <i>Payments received from the disposal of property, plant and equipment and intangible assets</i>	12	9	7	3
<b>Net cash outflow for P, P &amp; E and intangible assets</b>	<b>-54</b>	<b>-62</b>	<b>-12</b>	<b>-16</b>
<b>Free cash flow from continuing operations</b>	<b>-4</b>	<b>-181</b>	<b>137</b>	<b>32</b>
- <i>Thereof special items</i>	-60	-112	-14	-30
- <i>Adjusted free cash flow from operating activities of continuing operations</i>	56	-69	151	62
<b>Payments made / proceeds from the disposal of financial assets</b>	<b>0</b>	<b>-18</b>	<b>1</b>	<b>-3</b>
<b>Investments in financial assets</b>	<b>-1</b>	<b>-5</b>	<b>0</b>	<b>0</b>
<b>Changes in marketable securities <sup>1)</sup></b>	<b>28</b>	<b>-150</b>	<b>0</b>	<b>-60</b>
<b>Cash flow from financing activities of continuing operations</b>	<b>-167</b>	<b>-104</b>	<b>-36</b>	<b>-44</b>
- Share buyback	-111	-39	-26	-30
- Dividends	-44	-46	0	0
- Repayment of financial debt / borrowing	3	0	3	0
- Interest paid	-15	-19	-13	-14
<b>Change in cash and cash equivalents of continuing operations</b>	<b>-144</b>	<b>-458</b>	<b>102</b>	<b>-75</b>
<b>Change in cash and cash equivalents of discontinued operations</b>	<b>-16</b>	<b>37</b>	<b>0</b>	<b>52</b>
<b>Change in value of cash and cash equivalents due to changes in foreign exchange rates</b>	<b>-1</b>	<b>-1</b>	<b>0</b>	<b>1</b>
<b>Change in cash and cash equivalents</b>	<b>-161</b>	<b>-422</b>	<b>102</b>	<b>-22</b>
Cash and cash equivalents at January 1 / October 1	617	1,032	354	636
Change in cash and cash equivalents of assets classified as held for sale	-3	7	-3	3
<b>Cash and cash equivalents at December 31</b>	<b>453</b>	<b>617</b>	<b>453</b>	<b>617</b>

1) Marketable securities are included in net debt position



## Valuation net cash / net debt

€ million	Sep 30, 2018	Dec 31, 2018
Cash and cash equivalents	354	453
Marketable securities	120	120
Financial debt	-511	-513
<b>Net cash (+) / net debt (-)</b>	<b>-37</b>	<b>60</b>
Pension provisions	-292	-288
Financial assets (Apleona, JBN) <sup>1)</sup>	367	373
Future cash-out special items	~ -125	~ -100
Intra-year working capital swing	0	~ -50
<b>Valuation net cash (+) / net debt (-)</b>	<b>~ - 90</b>	<b>~ 0</b>



<sup>1</sup> Apleona PPN: 237m EUR, Vendor Claim Note (accrued value): 125m EUR, JBN: 11m EUR

# Disclaimer

This presentation has been produced for support of oral information purposes only and contains forward-looking statements which involve risks and uncertainties. Forward-looking statements are statements that are not historical facts, including statements about our beliefs and expectations. Such statements made within this document are based on plans, estimates and projections as they are currently available to Bilfinger SE. Forward-looking statements are therefore valid only as of the date they are made, and we undertake no obligation to update publicly any of them in light of new information or future events. Apart from this, a number of important factors could therefore cause actual results to differ materially from those contained in any forward-looking statement. Such factors include the conditions in worldwide financial markets as well as the factors that derive from any change in worldwide economic development.

This document does not constitute any form of offer or invitation to subscribe for or purchase any securities. In addition, the shares of Bilfinger SE have not been registered under United States Securities Law and may not be offered, sold or delivered within the United States or to U.S. persons absent registration under or an applicable exemption from the registration requirements of the United States Securities Law.